

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Olaparib is currently licensed in the European Union for people for whom chemotherapy is not clinically indicated. In a previous appraisal for [olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer](#), it was noted that people who cannot or should not have docetaxel (chemotherapy) are likely to be older.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

Differences in the prevalence cannot be addressed in a technology appraisal.

According to NICE's [manual](#) and [principles](#), the committee will consider whether its recommendation could have a detrimental impact on people protected by the equality legislation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
--

No.

Approved by Associate Director (name): Henry Edwards

Date: 31/01/2023